CanSino Biologics Inc (F:CJH) — Market Cap & Net Worth
Market Cap & Net Worth: CanSino Biologics Inc (CJH)
CanSino Biologics Inc (F:CJH) has a market capitalization of $390.87 Million (€334.33 Million) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #13426 globally and #1393 in its home market, demonstrating a -3.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CanSino Biologics Inc's stock price €2.52 by its total outstanding shares 132670900 (132.67 Million). See CanSino Biologics Inc capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
CanSino Biologics Inc Market Cap History: 2019 to 2026
CanSino Biologics Inc's market capitalization history from 2019 to 2026. Data shows change from $1.06 Billion to $390.87 Million (-5.27% CAGR).
CanSino Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CanSino Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.55x
CanSino Biologics Inc's market cap is 0.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20.81x
CanSino Biologics Inc's market cap is 20.81 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.06 Billion | $2.28 Million | -$156.77 Million | 465.31x | N/A |
| 2020 | $2.68 Billion | $18.54 Million | -$396.64 Million | 144.70x | N/A |
| 2021 | $3.04 Billion | $4.30 Billion | $1.91 Billion | 0.71x | 1.59x |
| 2022 | $1.20 Billion | $1.03 Billion | -$909.43 Million | 1.16x | N/A |
| 2023 | $418.79 Million | $345.18 Million | -$1.48 Billion | 1.21x | N/A |
| 2024 | $595.61 Million | $824.88 Million | -$378.88 Million | 0.72x | N/A |
| 2025 | $580.10 Million | $1.06 Billion | $27.87 Million | 0.55x | 20.81x |
Competitor Companies of CJH by Market Capitalization
Companies near CanSino Biologics Inc in the global market cap rankings as of August 4, 2026.
Key companies related to CanSino Biologics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
CanSino Biologics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, CanSino Biologics Inc's market cap moved from $1.06 Billion to $ 390.87 Million, with a yearly change of -5.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €390.87 Million | -32.62% |
| 2025 | €580.10 Million | -2.60% |
| 2024 | €595.61 Million | +42.22% |
| 2023 | €418.79 Million | -65.03% |
| 2022 | €1.20 Billion | -60.63% |
| 2021 | €3.04 Billion | +13.35% |
| 2020 | €2.68 Billion | +152.55% |
| 2019 | €1.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of CanSino Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $390.87 Million USD |
| MoneyControl | $390.87 Million USD |
| MarketWatch | $390.87 Million USD |
| marketcap.company | $390.87 Million USD |
| Reuters | $390.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more